Biopharma · FDA Approvals · Stock
QTRX Quanterix
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract resea…
Assets on file: pTau217
Catalyst calendar
Dated catalysts for QTRX, including recently decided ones.
Nothing scheduled in this window.
Recent first-hand events
Every first-hand event for QTRX, newest first.
QTRXQuanterixQuanterix expands licensing agreement with ALZpath for pTau217 antibody
Quanterix and ALZpath expanded their 2023 licensing agreement to broaden use of ALZpath's proprietary pTau217 antibody across the Simoa research portfolio for Alzheimer's biomarker research. The expansion supports development of more specific blood-based measures of disease pathology on the Simoa platform.
Peers by market cap
Companies in the same sector closest to QTRX in market value.
ORGOOrganogenesisMarket cap $132.5M · 1 tracked drug
TARAProtaraMarket cap $132.0M · 1 tracked drug · 3 upcoming catalysts
OTLKOutlook TherapeuticsMarket cap $137.2M · 1 tracked drug · 1 upcoming catalyst
ANTXAN2 TherapeuticsMarket cap $137.4M · 2 tracked drugs · 2 upcoming catalysts
RNAAtrium TherapeuticsMarket cap $139.6M · 1 tracked drug · 2 upcoming catalysts
CRDLCardiol TherapeuticsMarket cap $139.7M · 1 tracked drug
ARMPArmata PharmaceuticalsMarket cap $128.3M · 1 tracked drug · 1 upcoming catalyst
HURATuHURA BiosciencesMarket cap $128.1M · 3 tracked drugs